An analysis of the biochemical diagnosis of 66 pheochromocytomas

European Journal of Endocrinology

Volumn 156, Issue 5, 2007, Pages 569-575

  d'Herbomez, Michèle ^a   Forzy, Gérard ^b   Bauters, Catherine ^a   Tierny, Catherine ^a   Pigny, Pascal ^a   Carnaille, Bruno ^a   Pattou, François ^a   Wémeau, Jean Louis ^a   Rouaix, Nathalie ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Centre Hospitalier Saint Philibert GHICL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CHROMOGRANIN A; METADRENALIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; FAMILY HISTORY; FEMALE; GENETIC DISORDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; REFERENCE VALUE; ROC CURVE; SENSITIVITY AND SPECIFICITY; URINALYSIS;

ADRENAL GLAND NEOPLASMS; ADULT; CATECHOLAMINES; CHROMOGRANIN A; FEMALE; HUMANS; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE; STATISTICS, NONPARAMETRIC;

EID: 34249067687     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-06-0640     Document Type: Article

References (45)

1. Young WF Jr. Pheochromocytoma 1926-1993. Trends in Endocrinology and Metabolism 1993 4 122-127.
2. Lenders JW, Eisenhofer G, Manelli M & Pacak K. Phaeochromocytoma. Lancet 2005 366 665-675.
3. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y & Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocrine Reviews 2004 25 309-340.
4. Yeo H & Roman S. Pheochromocytoma and functional paraganglioma. Current Opinion in Oncology 2005 17 8-13.
5. Revol A, Cornoy E, Forzy G, Garnier JP, Gerhardt MF, Hirth C, Jacob N, Mathieu P, Patricot MC, Peyrin L, Diton A & Ruedas E. Recommended methods for the determination of catecholamines and their metabolites in urine. Significance of results in the diagnosis and follow-up of pheochromocytoma and neuroblastoma. Annales de Biologie Clinique 1994 52 625-637.
6. Plouin PF, Chatellier G, Grouzmann E, Azizi M, Denolle T, Comoy E & Corvol P. Plasma neuropeptide Y and catecholamine concentrations and urinary metanephrine excretion in patients with adrenal or ectopic phaeochromocytoma. Journal of Hypertension Supplement 1991 9 S272-S273.
7. Pagliari R, Cottet-Emard JM & Peyrin L. Determination of free and conjugated normetanephrine and metanephrine in human plasma by high-performance liquid chromatography with electrochemical detection. Journal of Chromatography 1991 563 23-36.
8. Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC, Kloppenborg PW, Thien T & Eisenhofer G. Plasma metanephrines in the diagnosis of pheochromocytoma. Annals of Internal Medicine 1995 123 101-109.
9. Bravo EL. Plasma or urinary metanephrines for the diagnosis of pheochromocytoma? That is the question. Annals of Internal Medicine 1996 125 331-332.
10. Kudva YC, Sawka AM & Young WF Jr. Clinical review 164: the laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. Journal of Clinical Endocrinology and Metabolism 2003 88 4533-4539.
11. Raber W, Raffesberg W, Bischof M, Scheuba C, Niederle B, Gasic S, Waldhausl W & Roden M. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Archives of Internal Medicine 2000 160 2957-2963.
12. Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS & Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. New England Journal of Medicine 1999 340 1872-1879.
13. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS & Eisenhofer G. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002 287 1427-1434.
14. Weise M, Merke DP, Pacak K, Walther MM & Eisenhofer G. Utility of plasma free metanephrines for detecting childhood pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 2002 87 1955-1960.
15. Lagerstedt SA, O'Kane DJ & Singh RJ. Measurement of plasma free metanephrine and normetanephrine by liquid chromatography-tandem mass spectrometry for diagnosis of pheochromocytoma. Clinical Chemistry 2004 50 603-611.
16. Bravo EL & Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocrine Reviews 2003 24 539-553.
17. Eisenhofer G, Walther M, Keiser HR, Lenders JW, Friberg P & Pacak K. Plasma metanephrines: a novel and cost-effective test for pheochromocytoma. Brazilian Journal of Medical and Biological Research 2000 33 1157-1169.
18. Sawka AM, Gafni A, Thabane L & Young WF Jr. The economic implications of three biochemical screening algorithms for pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 2004 89 2859-2866.
19. Sawka AM, Prebtani AP, Thabane L, Gafni A, Levine M & Young WF Jr. A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma. BioMed Central Endocrine Disorders 2004 4 2.
20. O'Connor DT & Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. New England Journal of Medicine 1986 314 1145-1151.
21. Taupenot L, Harper KL & O'Connor DT. The chromogranin-secretogranin family. New England Journal of Medicine 2003 348 1134-1149.
22. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R & Lamberts SW. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. Journal of Clinical Endocrinology and Metabolism 1997 82 2622-2628.
23. d'Herbomez M, Gouze V, Huglo D, Nocaudie M, Patton F, Proye C, Wemeau JL & Marchandise X. Chromogranin A assay and (131)I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma. Journal of Nuclear Medicine 2001 42 993-997.
24. Hsiao RJ, Neumann HP, Farmer RJ, Barbosa JA & O'Connor DT. Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. American Journal of Medicine 1990 88 607-613.
25. Bernini GP, Moretti A, Ferdeghini M, Ricci S, Letizia C, D'Erasmo E, Argenio GF & Salvetti A. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours. British Journal of Cancer 2001 84 636-642.
26. Bernini G, Moretti A, Fontana V, Orlandini C, Miccoli P, Berti P, Basolo F, Faviana P, Bardini M & Salvetti A. Plasma chromogranin A in incidental non-functioning, benign, solid adrenocortical tumors. European Journal of Endocrinology 2004 151 215-222.
27. Canale MP & Bravo EL. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. Journal of Clinical Endocrinology and Metabolism 1994 78 1139-1144.
28. Van de Herder WW, de Krijger RR, Bruining HA, Bonjer HJ, Lamberts SW, Van den Meiracker AH, Stijnen TH & Boomsma F. The value of plasma markers for the clinical behaviour of phaeochromocytomas. European Journal of Endocrinology 2002 147 85-94.
29. Bauters C, Leclerc L, Wemeau JL, Proye C, Pigny P & Porchet N. Multiple endocrine neoplasias. Recent advances in clinical and genetic diagnosis. Revue de Medecine Interne 2003 24 721-729.
30. Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B & Kirste G. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. New England Journal of Medicine 1993 329 1531-1538.
31. Candito, M, Billaud E, Chauffert M, Cottet-Emard JM, Desmoulin D, Garnier JP, Greffe J, Hirth C, Jacob N, Millot F, Nignan A, Patricot MC, Peyrin L & Plouin PF. Biochemical diagnosis of pheochromocytoma and neuroblastomas. Annales de Biologie Clinique 2002 60 15-36.
32. Wassell J, Reed P, Kane J & Weinkove C. Freedom from drug interference in new immunoassays for urinary catecholamines and metanephrines. Clinical Chemistry 1999 45 2216-2223.
33. Kushnir MM, Rockwood AL, Nelson GJ, Yue B & Urry FM. Analysis of catecholamines in urine by positive-ion electrospray tandem mass spectrometry. Clinical Chemistry 2002 48 323-331.
34. Taylor RL & Singh RJ. Validation of liquid chromatography-tandem mass spectrometry method for analysis of urinary conjugated metanephrine and normetanephrine for screening of pheochromocytoma. Clinical Chemistry 2002 48 533-539.
35. Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR & Pacak K. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. Journal of Clinical Endocrinology and Metabolism 2003 88 2656-2666.
36. Sawka AM, Thabane L, Gafni A, Levine M & Young WF Jr. Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: can specificity be improved by adjustment for age? BioMed Central Endocrine Disorders 2005 28 1.
37. Brain KL, Kay J & Shine B. Measurement of urinary metanephrines to screen for pheochromocytoma in an unselected hospital referral population. Clinical Chemistry 2006 52 2060-2064.
38. Biausque F, Jaboureck O, Devos P, D'Herbomez M, Hainaut P, Carre A & Mounier-Vehier C. Clinical significant of serum chromogranin A levels for diagnosing pheochromocytoma in hypertensive patients. Archives des Maladies du Coeur et des Vaisseau 2003 96 780-783.
39. Sawka AM, Jaeschke R, Singh RJ & Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. Journal of Clinical Endocrinology and Metabolism 2003 88 553-558.
40. Unger N, Pitt C, Schmidt IL, Walz MK, Schmid KW, Philipp T, Mann K & Petersenn S. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. European Journal of Endocrinology 2006 154 409-417.
41. Eisenhofer G, Goldstein DS, Sullivan P, Csako G, Brouwers FM, Lai EW, Adams KT & Pacak K. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. Journal of Clinical Endocrinology and Metabolism 2005 90 2068-2075.
42. Stridsberg M & Husebye ES. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. European Journal of Endocrinology 1997 136 67-73.
43. Degorce F, Goumon Y, Jacquemart L, Vidaud C, Bellanger L, Pons-Anicet D, Seguin P, Metz-Boutigue MH & Aunis D. A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). British Journal of Cancer 1999 79 65-71.
44. Grossrubatscher E, Dalino P, Vignati F, Gambacorta M, Pugliese R, Boniardi M, Rossetti O, Marocchi A, Bertuzzi M & Loli P. The role of chromogranin A in the management of patients with phaeochromocytoma. Clinical Endocrinology 2006 65 287-293.
45. Eisenhofer G, Huysmans F, Pacak K, Walther MM, Sweep FC & Lenders JW. Plasma metanephrines in renal failure. Kidney International 2005 67 668-677.